纳米抗体分子影像探针的研究进展  

Reserch progress of molecular imaging with radiolabeled nanobodies

作　　者：张友 黄钢[1] 魏伟军 刘建军[1] Zhang You;Huang Gang;Wei Weijun;Liu Jianjun(Department of Nuclear Medicine,Institute of Clinical Nuclear Medicine,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属仁济医院核医学科,上海交通大学医学院临床核医学研究所,上海200127

出　　处：《国际放射医学核医学杂志》2022年第9期555-560,共6页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：国家重点研发计划(2020YFA0909000);国家自然科学基金(82001878、82171972);上海市青年科技启明星计划(20QA1406100)。

摘　　要：纳米抗体凭借其优越的靶向性、稳定性、溶解度及组织穿透能力, 已成为分子影像领域中的热门靶向分子。多种基于纳米抗体的分子影像探针在临床前研究和临床试验中均已展现出良好的诊断效能。笔者主要介绍纳米抗体分子影像探针在肿瘤中的最新研究进展, 并进一步讨论其临床转化面临的挑战和应对策略。Nanobodies have become popular targeting molecules in the field of molecular imaging due to their excellent targeting ability,superior stability,good solubility,and enhanced tissue penetration ability.A variety of nanobody-based molecular imaging probes have shown great promise for noninvasive diagnosis of human malignancies in preclinical and clinical settings.This review mainly introduces the latest research progress on nanobody-based molecular imaging probes in tumors,and further discusses the challenges and strategies for future clinical translation.

关 键 词：分子探针 纳米抗体 放射免疫显像 正电子发射断层显像术 肿瘤诊断 

分 类 号：TB383.1[一般工业技术—材料科学与工程] R313[医药卫生—基础医学]